Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country
Purpose: Anaplastic lymphoma kinase (ALK) inhibitors are associated with good overall survival (OS) for ALK-positive metastatic non-small cell lung cancer (NSCLC). However, these treatments can be unavailable or limited by financial constraints in developing countries. Using data from a nationwide l...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Published: |
Dove Medical Press LTD
2023
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/39088/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.um.eprints.39088 |
---|---|
record_format |
eprints |
spelling |
my.um.eprints.390882023-11-30T02:16:07Z http://eprints.um.edu.my/39088/ Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country Poh, Mau Ern How, Soon Hin Ho, Gwo Fuang Pang, Yong Kek Hasbullah, Harissa H. Tho, Lye Mun Nor, Ibtisam Muhamad Lim, Bee Chiu Ho, Kean Fatt Thiagarajan, Muthukkumaran Samsudin, Azlina Omar, Azza Ong, Choo Khoon Soon, Sing Yang Tan, Justin Yu Kuan Abidin, Muhammad Adil Zainal RC0254 Neoplasms. Tumors. Oncology (including Cancer) Purpose: Anaplastic lymphoma kinase (ALK) inhibitors are associated with good overall survival (OS) for ALK-positive metastatic non-small cell lung cancer (NSCLC). However, these treatments can be unavailable or limited by financial constraints in developing countries. Using data from a nationwide lung cancer registry, the present study aimed to identify treatment patterns and clinical outcomes of ALK-positive NSCLC in Malaysia.Methods: This retrospective study examined data of patients with ALK-positive NSCLC from 18 major hospitals (public, private, or university teaching hospitals) throughout Malaysia between January 1, 2015 and December 31, 2020 from the National Cardiovascular and Thoracic Surgical Database (NCTSD). Data on baseline characteristics, treatments, radiological findings, and pathological findings were collected. Overall survival (OS) and time on treatment (TOT) were calculated using the Kaplan-Meier method.Results: There were 1581 NSCLC patients in the NCTSD. Based on ALK gene-rearrangement test results, only 65 patients (4.1%) had ALK-positive advanced NSCLC. Of these 65 patients, 59 received standard-of-care treatment and were included in the analysis. Crizotinib was the most commonly prescribed ALK inhibitor, followed by alectinib and ceritinib. Patients on ALK inhibitors had better median OS (62 months for first-generation inhibitors, not reached at time of analysis for second-generation inhibitors) compared to chemotherapy (27 months), but this was not statistically significant (P=0.835) due to sample-size limitations. Patients who received ALK inhibitors as first-line therapy had significantly longer TOT (median of 11 months for first-generation inhibitors, not reached for second-generation inhibitors at the time of analysis) compared to chemotherapy (median of 2 months; P<0.01).Conclusion: Patients on ALK inhibitors had longer median OS and significantly longer TOT compared to chemotherapy, suggesting long-term benefit. Dove Medical Press LTD 2023 Article PeerReviewed Poh, Mau Ern and How, Soon Hin and Ho, Gwo Fuang and Pang, Yong Kek and Hasbullah, Harissa H. and Tho, Lye Mun and Nor, Ibtisam Muhamad and Lim, Bee Chiu and Ho, Kean Fatt and Thiagarajan, Muthukkumaran and Samsudin, Azlina and Omar, Azza and Ong, Choo Khoon and Soon, Sing Yang and Tan, Justin Yu Kuan and Abidin, Muhammad Adil Zainal (2023) Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country. Cancer Management And Research, 15. pp. 31-41. ISSN 1179-1322, DOI https://doi.org/10.2147/CMAR.S393729 <https://doi.org/10.2147/CMAR.S393729>. 10.2147/CMAR.S393729 |
institution |
Universiti Malaya |
building |
UM Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Universiti Malaya |
content_source |
UM Research Repository |
url_provider |
http://eprints.um.edu.my/ |
topic |
RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
spellingShingle |
RC0254 Neoplasms. Tumors. Oncology (including Cancer) Poh, Mau Ern How, Soon Hin Ho, Gwo Fuang Pang, Yong Kek Hasbullah, Harissa H. Tho, Lye Mun Nor, Ibtisam Muhamad Lim, Bee Chiu Ho, Kean Fatt Thiagarajan, Muthukkumaran Samsudin, Azlina Omar, Azza Ong, Choo Khoon Soon, Sing Yang Tan, Justin Yu Kuan Abidin, Muhammad Adil Zainal Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country |
description |
Purpose: Anaplastic lymphoma kinase (ALK) inhibitors are associated with good overall survival (OS) for ALK-positive metastatic non-small cell lung cancer (NSCLC). However, these treatments can be unavailable or limited by financial constraints in developing countries. Using data from a nationwide lung cancer registry, the present study aimed to identify treatment patterns and clinical outcomes of ALK-positive NSCLC in Malaysia.Methods: This retrospective study examined data of patients with ALK-positive NSCLC from 18 major hospitals (public, private, or university teaching hospitals) throughout Malaysia between January 1, 2015 and December 31, 2020 from the National Cardiovascular and Thoracic Surgical Database (NCTSD). Data on baseline characteristics, treatments, radiological findings, and pathological findings were collected. Overall survival (OS) and time on treatment (TOT) were calculated using the Kaplan-Meier method.Results: There were 1581 NSCLC patients in the NCTSD. Based on ALK gene-rearrangement test results, only 65 patients (4.1%) had ALK-positive advanced NSCLC. Of these 65 patients, 59 received standard-of-care treatment and were included in the analysis. Crizotinib was the most commonly prescribed ALK inhibitor, followed by alectinib and ceritinib. Patients on ALK inhibitors had better median OS (62 months for first-generation inhibitors, not reached at time of analysis for second-generation inhibitors) compared to chemotherapy (27 months), but this was not statistically significant (P=0.835) due to sample-size limitations. Patients who received ALK inhibitors as first-line therapy had significantly longer TOT (median of 11 months for first-generation inhibitors, not reached for second-generation inhibitors at the time of analysis) compared to chemotherapy (median of 2 months; P<0.01).Conclusion: Patients on ALK inhibitors had longer median OS and significantly longer TOT compared to chemotherapy, suggesting long-term benefit. |
format |
Article |
author |
Poh, Mau Ern How, Soon Hin Ho, Gwo Fuang Pang, Yong Kek Hasbullah, Harissa H. Tho, Lye Mun Nor, Ibtisam Muhamad Lim, Bee Chiu Ho, Kean Fatt Thiagarajan, Muthukkumaran Samsudin, Azlina Omar, Azza Ong, Choo Khoon Soon, Sing Yang Tan, Justin Yu Kuan Abidin, Muhammad Adil Zainal |
author_facet |
Poh, Mau Ern How, Soon Hin Ho, Gwo Fuang Pang, Yong Kek Hasbullah, Harissa H. Tho, Lye Mun Nor, Ibtisam Muhamad Lim, Bee Chiu Ho, Kean Fatt Thiagarajan, Muthukkumaran Samsudin, Azlina Omar, Azza Ong, Choo Khoon Soon, Sing Yang Tan, Justin Yu Kuan Abidin, Muhammad Adil Zainal |
author_sort |
Poh, Mau Ern |
title |
Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country |
title_short |
Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country |
title_full |
Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country |
title_fullStr |
Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country |
title_full_unstemmed |
Real-world treatment and outcomes of ALK-positive metastatic non-small cell lung cancer in a Southeast Asian country |
title_sort |
real-world treatment and outcomes of alk-positive metastatic non-small cell lung cancer in a southeast asian country |
publisher |
Dove Medical Press LTD |
publishDate |
2023 |
url |
http://eprints.um.edu.my/39088/ |
_version_ |
1784511861983543296 |
score |
13.18916 |